Irina Krykbaeva, PhD, Awarded 2022 Milton C. Winternitz Prize in Pathology
Irina Krykbaeva, a recent PhD graduate in the Department of Pathology at Yale School of Medicine, is the winner of the 2022 Milton C. Winternitz Prize in Pathology. The prize is awarded annually to the student who, in the opinion of the department faculty and staff, has done outstanding work in the course.
Yale Pathology Diagnostic Pathology CME Annual Review Scheduled for September 17-18 at Yale Club of NYC
The Yale Department of Pathology presents its inaugural Diagnostic Pathology CME Annual Review on September 17-18 at the Yale Club of New York City. This inaugural course at the Yale Club in the heart of Midtown Manhattan will focus on the recent World Health Organization updates in all major pathology subspecialties.
Gender advocacy leads to major recognition for Yale oncologist Pamela Kunz, MD
Pamela Kunz, MD, was recently recognized as the 2021 Woman Oncologist of the Year by Women Leaders in Oncology for her commitment to advancing diversity, equity, and inclusion (DEI) through her research, committee leadership, and talks. “My advocacy is what is being recognized,” Kunz said, “To have the award acknowledge my DEI efforts is really meaningful.”
For Teens Living with Cancer, Keeping Life as 'Normal' as Possible
Yale New Haven Children's Hospital has opened the Lauren Telesz/Smilow Teen Center, to fill an important gap between pediatric and adult cancer care. The center dovetails with a larger goal to help improve survival rates for adolescents and young adults with cancer.Source: Yale Medicine
Yale Cancer Center receives $100,000 from Hyundai
Hyundai presented the Yale Cancer Center with $100,000 on Wednesday. It is all part of the company's Hope on Wheels initiative. On Wednesday, the award was handed over to Dr. Shilpa Hattangadi of Yale Cancer Center at Smilow Cancer Hospital.Source: WTNH
Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'
Connecticut Magazine has named 77 Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven physicians and surgeons to its 2018 Best Doctors guide. Published in the magazine's April issue, the Best Doctors list consists of 779 Connecticut physicians from 78 medical specialties.
Most pediatric oncologists willing to consider medical marijuana for children with cancer
A majority of pediatric cancer providers endorse the use of medical marijuana for children with advanced cancer, according to results of a multicenter survey published in Pediatrics. However, providers who are legally eligible to certify medical marijuana use appeared more cautious, results showed.Source: HemOnc Today
Opportunities to vaccinate young women against HPV missed at alarming rate
en aged 18-26 who were eligible to receive Human Papilloma Virus (HPV) vaccine have missed at least one opportunity to receive the vaccine during a visit to an obstetrics and gynecology clinic, Yale researchers report. This study also confirms previous research showing racial disparities in vaccination for HPV: Women who identify as black are 61% more likely have had a missed opportunity than women who identify as white. These findings are published in the American Journal of Obstetrics and Gynecology. HPV is a well-known cause of pre-cancerous cervical lesions, which, if untreated, could develop into cervical cancer. Immunization against HPV has been shown to be safe and effective in preventing these pre-cancerous lesions. The two-dose HPV vaccine is recommended for administration to It is recommended that girls ages 11-12 receive the two-dose HPV vaccine, and that those through age 26 receive the three-dose vaccination for “catch-up.”
Pediatric cancer providers give medical marijuana a cautious thumbs-up
New research by Yale Cancer Center (YCC) researchers shows a majority of pediatric cancer providers endorse the potential use of medical marijuana for children with advanced cancer, although providers who are legally eligible to certify its use are more cautious than those who aren’t. The findings also show clinicians would prefer to see much stronger clinical evidence that marijuana treatments can help in relieving symptoms, such as nausea and pain.
Medical Marijuana For Children With Cancer Broadly Supported By Doctors
An overwhelming majority of health care professionals who care for children with cancer would be willing to help those children get medical marijuana—though less enthusiastically if they happen to be among the providers who are actually eligible to provide it, found a new study. In a survey of pediatric oncology providers published in Pediatrics, 85% of providers who were certified to provide access to medical marijuana would be willing to help children with cancer access it, compared to 95% of their colleagues who lacked the ability to provide it. “Several studies over the past decade have ascertained that physicians are apprehensive about adult use of medical marijauna,” wrote Prasanna Ananth, MD, MPH, a pediatric oncologist/hematologist at Yale School of Medicine in New Haven, Connecticut, and fellow researchers.Source: Forbes
Mystery of breast cancer risk gene solved, 20 years after its discovery
More than 20 years after scientists revealed that mutations in the BRCA1 gene predispose women to breast cancer, Yale scientists have pinpointed the molecular mechanism that allows those mutations to wreak their havoc. The findings, reported Oct. 4 in the journal Nature, will not only help researchers design drugs to combat breast and ovarian cancers, but also help identify women who are at high risk of developing them, the authors say. “There have been about 14,000 papers written about BRCA1, and you would think we already know everything about the gene, but we don’t,” said senior author Patrick Sung, professor of molecular biophysics and biochemistry and of therapeutic radiology and member of the Yale Cancer Center.
$1.8 Million Granted to Yale School of Public Health to Study Effectiveness of HPV Vaccine
A $1.8 million National Institutes of Health grant will help researchers at the Yale School of Public Health shed light on the real-world effectiveness of the Human Papillomavirus (HPV) vaccine. Results of this study can ultimately help to maximize the vaccine’s impact on several types of cancer.